|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-4
|
|
pubmed:abstractText |
background: Mutations of the BCR-ABL tyrosine kinase domain constitute a major cause of resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. We sought to improve the diagnostic armamentarium by screening and to analyze the dynamics of mutated clones in chronic myeloid leukemia patients who experienced hematologic or cytogenetic relapse.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
186-92
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18223278-Adult,
pubmed-meshheading:18223278-Aged,
pubmed-meshheading:18223278-Amino Acid Substitution,
pubmed-meshheading:18223278-Chromatography, High Pressure Liquid,
pubmed-meshheading:18223278-Clinical Trials as Topic,
pubmed-meshheading:18223278-Drug Resistance, Neoplasm,
pubmed-meshheading:18223278-Female,
pubmed-meshheading:18223278-Fusion Proteins, bcr-abl,
pubmed-meshheading:18223278-Genes, abl,
pubmed-meshheading:18223278-Humans,
pubmed-meshheading:18223278-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18223278-Male,
pubmed-meshheading:18223278-Middle Aged,
pubmed-meshheading:18223278-Piperazines,
pubmed-meshheading:18223278-Point Mutation,
pubmed-meshheading:18223278-Predictive Value of Tests,
pubmed-meshheading:18223278-Protein Kinase Inhibitors,
pubmed-meshheading:18223278-Protein Structure, Tertiary,
pubmed-meshheading:18223278-Protein-Tyrosine Kinases,
pubmed-meshheading:18223278-Pyrimidines,
pubmed-meshheading:18223278-Recurrence,
pubmed-meshheading:18223278-Retrospective Studies
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
|
|
pubmed:affiliation |
III. Medizinische Klinik, Medizinische, Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
